Thursday, 18 May 2017

2 more weeks and abstracts are out!


Only 2 more weeks till the next trip to the windy city



so high time to check the ASCO abstracts here

Same procedure as every year, so please add the talks, abstracts and posters that you find particularly relevant as comments to this very post. 


And we will do our best to cover them on the blog!



18 comments:

  1. IDO inhibitor plus Nivo - first data
    http://www.businesswire.com/news/home/20170517006349/en/Data-Combination-Epacadostat-Opdivo%C2%AE-nivolumab-Highlighted-ASCO

    ReplyDelete
  2. https://globenewswire.com/news-release/2017/05/17/987467/0/en/Syndax-Announces-Results-from-Phase-2-ENCORE-601-Trial-of-Entinostat-in-Combination-with-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Advanced-Melanoma.html#.WR01htSjqzw.twitter Early trial data for patients progressing on anti pd1 small trial numbers but being extended

    ReplyDelete
  3. This comment has been removed by the author.

    ReplyDelete
  4. Abstract 9508
    A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets):The Anti-PD1 Brain Collaboration (ABC)'' http://abstracts.asco.org/199/AbstView_199_187928.html

    ReplyDelete
  5. This comment has been removed by the author.

    ReplyDelete
  6. Abstract 9545
    KEYNOTE-029:Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.
    http://abstracts.asco.org/199/AbstView_199_190321.html

    ReplyDelete
  7. Abstract e21044
    Being overweight is helping apparently. ''Analysis of the impact of body mass index in the treatment of metastatic melanoma with ipilimumab.
    http://abstracts.asco.org/199/AbstView_199_192081.html

    ReplyDelete
  8. Abstract 9565
    Evaluation of the Melanoma Tumor Burden Score (MTBS) in a real-world setting.
    http://abstracts.asco.org/199/AbstView_199_189148.html

    ReplyDelete
  9. Abstract e21032
    A pilot study of individualised monitoring of patients with metastatic melanoma using plasma and urine DNA.
    http://abstracts.asco.org/199/AbstView_199_186819.html

    ReplyDelete
  10. Abstract 9587
    IPI+ NIVO as neoadjuvant- firt data we heard at ESMO -2016. Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.
    http://abstracts.asco.org/199/AbstView_199_193232.html

    ReplyDelete
  11. Abstract 9500
    A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms.
    http://abstracts.asco.org/199/AbstView_199_189552.html

    ReplyDelete
  12. Best abstracts to be followed at ASCO highlighted in Medscape
    http://www.medscape.com/viewarticle/880602
    Keynote 026
    Combi d
    Combi MB
    CheckMate 204
    ECOG/intergroup 1609 trial

    ReplyDelete
  13. This comment has been removed by the author.

    ReplyDelete
  14. Hello Iain,

    Can you cover the imcgp100 trial currently running in the UK please. I am considering it.
    Many thanks Liam F

    ReplyDelete
    Replies
    1. Which abstract is that, Liam?

      Delete
  15. Poster Session #189 Saturday 3 june : Preliminary results from the international neoadjuvant melanoma consortium (INMC). http://abstracts.asco.org/199/AbstView_199_184819.html

    ReplyDelete

Immunotherapy in melanoma -what other cancers could learn from us

J. Weber on the checkpoint inhibitors in Melanoma -what other cancers could learn from us Relevant for us and other cancers: -the  ...